What happens when you stop taking semaglutide or tirzepatide

What happens when you stop taking semaglutide or tirzepatide

Stopping semaglutide or tirzepatide is one of the most-searched questions in GLP-1 care right now, and for good reason: whether someone is on a compounded plan, a branded prescription, or just thinking about coming off treatment eventually, the underlying biology works the same way. These medications reduce appetite and slow digestion while you're taking them. When you stop, that effect fades over time, and for most people, some or all of the lost weight gradually returns.

The clearest data on this comes from three randomized clinical trials of the branded, FDA-approved medications — semaglutide (marketed as Wegovy®) and tirzepatide (marketed as Zepbound®). No published clinical trial has directly studied stopping compounded semaglutide or compounded tirzepatide, the versions prepared by US-licensed 503A pharmacies that Cora Health connects patients with licensed providers to access. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products — so the trial numbers below describe what's been measured in the branded products and the biology behind them, not a guarantee of an identical experience with a compounded version. Individual results vary.

What the trials show about weight regain

Three trials, each looking at a different phase of treatment, point the same direction: continuing treatment maintains weight loss, and stopping leads to regain.

Why the weight tends to come back

These are three different designs — an extension study measuring what happens after full withdrawal (STEP 1), and two "continue vs. switch-to-placebo" trials starting mid-treatment (STEP 4, SURMOUNT-4) — but they converge on the same finding. As the STEP 1 extension authors put it directly: the results "confirm the chronicity of obesity" and "suggest ongoing treatment is required to maintain improvements in weight and health." All three trials studied the branded, FDA-approved products; individual results vary, and no equivalent trial exists for compounded versions.

The mechanism is pharmacological, not a matter of willpower. Semaglutide and tirzepatide work by mimicking gut hormones (GLP-1, and for tirzepatide, GIP as well) that signal fullness to the brain and slow stomach emptying. Semaglutide has an elimination half-life of roughly 145–168 hours — about one week — meaning its effects fade gradually over several weeks after the last dose rather than stopping abruptly. As blood levels drop, the appetite signals that were being suppressed drift back toward their pre-treatment baseline, and for most people that means hunger and food intake gradually increase again. The STEP 1 extension data reflects this beyond weight alone: blood pressure, C-reactive protein, and blood sugar improvements seen during treatment also drifted back toward baseline over the same year.

Side effects of stopping — and what isn't a withdrawal syndrome

People considering stopping often ask whether they'll experience "withdrawal." Based on current evidence, semaglutide and tirzepatide are not associated with a physical dependence or withdrawal syndrome in the way that term applies to medications like opioids or benzodiazepines — there's no evidence the body becomes chemically dependent on them. What people commonly notice after stopping is appetite and cravings returning, portion sizes creeping back up, and — per the trial data above — a gradual reversal of the blood pressure, blood sugar, and other cardiometabolic improvements gained during treatment.

Some of the most common on-treatment side effects (nausea, constipation, and other GI symptoms) typically ease once the medication clears the system: in STEP 4, gastrointestinal events were reported in 49.1% of people who continued semaglutide versus 26.1% of those switched to placebo, consistent with GI effects fading off-treatment. None of this reflects something having gone wrong — it's the medication's effect wearing off, not a complication of stopping. Individual results vary, and any new or concerning symptom after stopping should be discussed with a licensed provider.

Is there a required tapering schedule?

Not according to current FDA labeling. The FDA-approved prescribing information for Wegovy® (semaglutide) injection does not specify a required tapering schedule for discontinuing treatment. That doesn't mean a gradual adjustment is never used — some providers factor a patient's individual history and response into how they manage a change in treatment — but there's no single official protocol that applies to everyone. This is a clinical decision that belongs to the patient and their licensed provider, based on the patient's health history, goals, and how they've responded to treatment. Nothing in this article is dosing instruction — a licensed provider makes and guides that decision.

How people and providers approach the decision to stop

People stop GLP-1 medication for many reasons: reaching a personal goal weight, cost, side effects, a change in health status, insurance coverage changes, or simply wanting a break. None of those reasons is inherently right or wrong — they're individual circumstances that a licensed provider can help weigh.

What the research above suggests is that obesity behaves like other chronic conditions — comparable in this sense to hypertension or type 2 diabetes — where stopping treatment often means the condition's underlying drivers reassert themselves. That's part of why many clinicians frame GLP-1 therapy as an ongoing management plan rather than a fixed course. It doesn't mean stopping is the wrong call for a given person; it means the decision benefits from a plan: what to monitor, what changes to expect, and how to adjust nutrition and activity habits around the transition.

Cora's plans include ongoing provider monitoring throughout treatment for exactly this kind of question, so if or when someone is weighing whether to continue, adjust, or stop, it comes up as a scheduled conversation with a licensed provider rather than a decision made alone.

FAQ: stopping semaglutide or tirzepatide

Is there a withdrawal syndrome from stopping semaglutide or tirzepatide? No formal drug-withdrawal syndrome has been documented for either medication. What most people experience is a return of appetite and a gradual reversal of the metabolic improvements (blood pressure, blood sugar) gained during treatment, as the medication's effect fades over the following weeks. Individual results vary.

How much weight will I regain after stopping? It varies by person and by trial. In the STEP 1 extension, participants regained 11.6 percentage points of lost weight — about two-thirds of what they'd lost — within a year off treatment. In SURMOUNT-4, the group switched off tirzepatide regained 14.0% over the following year while the group that continued lost an additional 5.5%. These figures are from trials of the branded products; individual results vary, and a licensed provider can help set realistic expectations for your specific situation.

Do I need to taper off semaglutide or tirzepatide? The current FDA-approved label doesn't specify a required tapering schedule. Whether any adjustment makes sense for you is a decision to make with your licensed provider, not a do-it-yourself protocol.

Can I restart semaglutide or tirzepatide after stopping? The trials described here didn't test restarting after a full stop, so there's no trial data directly answering this. Because obesity is generally treated as an ongoing condition rather than a one-time course, many clinicians do discuss restarting as an option — that's a conversation to have with your provider based on your health history.

Are compounded semaglutide and compounded tirzepatide backed by the same trial data? The trial data in this article — STEP 1, STEP 4, and SURMOUNT-4 — was collected using the FDA-approved branded products (Wegovy® and Zepbound®). Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not therapeutically equivalent to those branded products, even though they use the same active ingredient. A licensed provider — not a platform — determines whether compounded medication is appropriate for a given patient.

Sources

Trial data reflects the branded, FDA-approved products studied; findings on compounded versions have not been independently trialed. Always confirm current prescribing information and discuss your specific situation with a licensed provider.

• STEP 1 trial extension — Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 2022. pubmed.ncbi.nlm.nih.gov/35441470
• STEP 4 — Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, 2021. pubmed.ncbi.nlm.nih.gov/33755728
• SURMOUNT-4 — Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, 2024. pubmed.ncbi.nlm.nih.gov/38078870
• STEP 1 (original trial, 14.9% figure) — Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. nejm.org
• SURMOUNT-1 (original trial, 22.5% figure) — Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. nejm.org
• FDA-approved prescribing information — WEGOVY (semaglutide) injection label. accessdata.fda.gov
• Semaglutide pharmacokinetics (half-life) — Yang X-D, Yang Y-Y. "Clinical Pharmacokinetics of Semaglutide: A Systematic Review." Drug Design, Development and Therapy, 2024. pmc.ncbi.nlm.nih.gov/PMC11215664